MK0767 Glipizide Comparator Cardiac Safety Study (0767-018)
NCT ID: NCT00543010
Last Updated: 2015-06-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
247 participants
INTERVENTIONAL
2002-11-30
2003-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
MK0767 and Metformin Combination Study (0767-028)
NCT00543738
Study MK0767 and Metformin in Type 2 Diabetic Patients (0767-020)
NCT00543361
Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans
NCT01762046
Placebo Controlled Metformin and Sulfonylurea Combination Study in Patients With Type 2 Diabetes (0767-025)
NCT00543751
Effect of Gemigliptin Versus Glimepiride on Cardiac Diastolic Function in Patients With Type 2 Diabetes
NCT05663736
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MK0767
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 21 to 80
Exclusion Criteria
* Currently on estrogen replacement therapy regimen
* Currently on a weight loss program with ongoing weight loss or taking medications for weight loss
* Having surgery 30 days before starting the study
* Have taken any other investigational drug in the past 90 days
* Have Hepatitis B or C
* Active liver or gallbladder disease
21 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2007_644
Identifier Type: -
Identifier Source: secondary_id
0767-018
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.